GSK (GLAXF)
GSK (GLAXF) Stock Price, Analysis & Data
| Precio de compra | n/a |
| Capitalización de mercado | 101.54B |
| Ingresos (TTM) | 33.2B |
| Beneficio neto (TTM) | 4.82B |
| Beta | 0.29 |
| EPS (TTM) | 1.59 |
| Ratio PER (TTM) | 15.94 |
| Adelante PE | 11.52 |
| P/B (TTM) | 4.28 |
| P/S (TTM) | 3.06 |
| Earnings Date | Oct 28, 2026 |
| Precio de venta | n/a |
| Volumen | 150 |
| Volumen medio (20D) | 740 |
| Abierto | 24.29 |
| Anterior Cerrar | 25.42 |
| Rango del día | 24.29 - 24.29 |
| Rango de 52 semanas | 18.99 - 31.48 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | $0.92 (3.61%) |
| Fecha ex dividendo | 13 ago 2026 |
Acerca de GLAXF
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respirator...
Desempeño financiero
En 2025, los ingresos de GSK fueron 32.67B, un aumento de 4.11% en comparación con 31.38B del año anterior. Las ganancias fueron 5.72B, un aumento de 121.98%.
Estados financierosLos analistas proyectan ingresos de ... Actualizar
2 semanas hace · Simply Wall St.
GSK (LSE:GSK) Opens Cambridge Research Hub And Teams Up With Relation TherapeuticsGSK (LSE:GSK) plans to establish a new global R&D centre on the Cambridge Biomedical Campus in the UK. The site is expected to accommodate more than 1,000 scientists and support closer work with nearb...